{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:09:27Z","timestamp":1720609767963},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1157\/13126271","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T18:15:16Z","timestamp":1227377716000},"page":"38-44","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S8","title":["\u00bfSon iguales todas las combinaciones de an\u00e1logos?"],"prefix":"10.1016","volume":"26","author":[{"given":"Celia","family":"Miralles \u00c1lvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13126271_bib1","unstructured":"Services PoAGfAaADoHaH. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008. p. 1-128."},{"key":"10.1157\/13126271_bib2","unstructured":"EACS. Society EAC. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe; 2007."},{"key":"10.1157\/13126271_bib3","unstructured":"Sida PdedGyPNse. Recomendaciones de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizada, Ene 2008). 2008."},{"key":"10.1157\/13126271_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1468-1293.2007.00451.x","article-title":"National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients","volume":"8","author":"Hart","year":"2007","journal-title":"HIV Med"},{"key":"10.1157\/13126271_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13126271_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0166-3542(01)00210-8","article-title":"Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors","volume":"54","author":"Cihlar","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1157\/13126271_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13126271_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13126271_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13126271_bib10","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2007","article-title":"Threeyear safety and efficacy of emtricitabine (FT)\/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine\/lamivudine (CBV) in antiretroviral treatment-na\u00efve patients","author":"Arribas","year":"2007"},{"key":"10.1157\/13126271_bib11","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Switching from Combivir to Truvada Preserves Limb Fat: Results of a DEXA Sub-Study of a 48-Week Randomized Study","author":"Graeme Moyle","year":"2008"},{"key":"10.1157\/13126271_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults","volume":"39","author":"DeJes\u00fas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126271_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126271_bib14","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention","article-title":"PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030)","author":"Mallal","year":"2007"},{"key":"10.1157\/13126271_bib15","series-title":"4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention","article-title":"High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity","author":"Saag","year":"2007"},{"key":"10.1157\/13126271_bib16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment","volume":"40","author":"Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126271_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126271_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13126271_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","article-title":"The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients","volume":"83","author":"Kiser","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13126271_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13126271_bib21","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Efficacy and safety of once-daily atazanavir\/ritonavir compared to twicedaily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naive HIV-1-infected subjects: the CASTLE Study, 48-week Results","author":"Molina","year":"2008"},{"key":"10.1157\/13126271_bib22","unstructured":"DeJes\u00fas E, Khanlou H, Ortiz R, Veronin E, Van Lunzen J, Andrade-Villanueva J, et al, editors. Efficacy and safety of duranavir\/ritonavir vs. lopinavir\/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS. Chicago, Illinois. September 17-20, 2007."},{"key":"10.1157\/13126271_bib23","series-title":"Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention","article-title":"Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada\u00ae) vs. abacavir plus lamivudine (Kivexa\u00ae) in patients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO study","author":"Mart\u00ednez","year":"2007"},{"key":"10.1157\/13126271_bib24","series-title":"15th CROI. Boston","article-title":"Efficacy and safety of abacavir\/lamivudine compared to tenofovir\/emtricitabine in combination with once-daily lopinavir\/ritonavir through 48 weeks in the HEAT Study","author":"Smith","year":"2008"},{"key":"10.1157\/13126271_bib25","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study","author":"Sabin","year":"2008"},{"key":"10.1157\/13126271_bib26","unstructured":"Diseases NIAD. NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC\/3TC Found Less Effective in Subgroup of Antiretroviral-Na\u00efve Individuals. En: Health NI, editor. USA; 2008."}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08765303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T05:57:28Z","timestamp":1545631048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08765303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":26,"alternative-id":["S0213005X08765303"],"URL":"https:\/\/doi.org\/10.1157\/13126271","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}